IceCure Medical Highlights Newly Published Peer-Reviewed Journal Article Presenting Key Clinical Advantages Of Cryoablation Over Radiofrequency Ablation For Early-Stage Breast Cancer
IceCure Medical Ltd. ICCM | 0.00 |
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients
IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the world's top 20 medical device companies
CAESAREA, Israel, June 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlights a newly published peer-reviewed journal article presenting key clinical advantages of cryoablation over radiofrequency ablation ("RFA") for early-stage breast cancer, as the Company prepares to participate in the 34th Annual Meeting of the Japanese Breast Cancer Society ("JBCS"), taking place on June 25-27, 2026 in Kyoto, Japan.
